Doptelet Shortage: What Providers and Prescribers Need to Know in 2026

For hematologists, hepatologists, oncologists, and other prescribers, navigating the specialty pharmacy system for Doptelet (avatrombopag) is an increasingly important clinical skill. As of 2026, Doptelet remains off the FDA shortage list, but access challenges related to restricted distribution and prior authorization create real delays that can impact patient care — particularly for chronic liver disease (CLD) patients with time-sensitive procedure windows.

Current Availability Status: 2026 Summary

Doptelet is not on the FDA Drug Shortage Database as of 2026. AkaRx (Sobi North America) has maintained consistent production since initial FDA approval in May 2018. The July 2025 pediatric approval for ITP patients one year and older expanded demand but has not triggered reported supply constraints. Your patients' challenges in obtaining Doptelet are typically distribution and insurance process challenges, not manufacturing gaps.

Understanding Doptelet's Restricted Distribution Model

Doptelet is classified as a specialty medication and is available only through:

Specialty pharmacies within the Doptelet network (authorized by Sobi/AkaRx)

Dispensing physician practices with in-office pharmacy capabilities

Retail pharmacies, including large chains, are not authorized to carry Doptelet. Sending a prescription to a non-network pharmacy will result in the patient being unable to fill it. Ensure your prescription routing goes through Doptelet Connect.

The Doptelet Connect Enrollment Process

Doptelet Connect, managed by AssistRx, is the hub for patient enrollment, insurance verification, prior authorization support, and pharmacy routing. Here is the clinical workflow:

Complete the Prescription Enrollment Form (available on doptelethcp.com).

Submit via Doptelet Connect portal, fax to 1-855-686-8729, or email to DopteletConnect@AssistRx.com.

Doptelet Connect processes the benefit investigation (BI) to determine patient coverage and identify prior authorization requirements.

The PA is submitted by the specialty pharmacy on your behalf; your office may need to provide clinical notes, lab values (platelet counts), and diagnosis codes.

Upon approval, the specialty pharmacy ships Doptelet directly to the patient.

Prior Authorization: What Clinical Criteria Are Typically Required

Based on published utilization management guidelines, prior authorization criteria for Doptelet typically include:

For CLD indication: Documented chronic liver disease diagnosis; platelet count baseline below 50×10⁹/L; scheduled elective procedure; duration limited to 5 days; dose does not exceed 60 mg (3 × 20 mg tablets per day); maximum of 15 tablets per treatment course.

For ITP indication: Confirmed ITP diagnosis; documentation of prior treatment failure (corticosteroids, IVIG, or other); platelet count below 30×10⁹/L or evidence of clinically significant bleeding; monthly platelet count monitoring.

Some plans implement step therapy, requiring prior failure with Promacta (eltrombopag) or Nplate (romiplostim) before approving Doptelet. Having documentation of any prior TPO-RA use readily available will expedite the PA process.

Timing Considerations for CLD Patients With Scheduled Procedures

For CLD patients, the therapeutic window for Doptelet is precise. Based on the prescribing information and ADAPT-1/ADAPT-2 trial protocols:

Doptelet should be administered once daily for 5 consecutive days.

The procedure should be scheduled 5 to 8 days after the last dose.

Therefore, the first dose should be given 10 to 13 days before the procedure.

Given 2- to 4-week PA timelines, initiate Doptelet Connect enrollment at least 5 to 6 weeks before the planned procedure date.

Escalation Pathways When Access Is Delayed

When standard PA timelines conflict with clinical urgency, providers have these escalation options:

Contact your Doptelet field reimbursement manager at Doptelet.escalation@sobi.com, including your practice name, contact, phone, state, and ZIP code.

Request an urgent PA or peer-to-peer review with the insurance medical director for time-sensitive CLD procedures.

For ITP patients with acute bleeding risk, document the clinical urgency in the PA letter.

Consider using medfinder for providers to help identify available dispensing locations for your patients.

Key ICD-10 Codes for Doptelet Prior Authorization

D69.3 — Immune thrombocytopenic purpura (ITP)

D69.59 — Other secondary thrombocytopenia

K74.60 — Unspecified cirrhosis of liver (for CLD indication)

K74.69 — Other cirrhosis of liver

Patient Financial Assistance: What to Communicate to Your Billing Staff

Doptelet Connect offers copay assistance for commercially insured patients, and a patient assistance program for those without coverage. A free trial offer is available to eligible new ITP patients. For a full breakdown of patient savings programs, see our detailed guide: How to Help Your Patients Save Money on Doptelet: A Provider's Guide to Savings Programs.